Cargando…

Is the Harm-to-Benefit Ratio a Key Criterion in Vaccine Approval?

Detalles Bibliográficos
Autores principales:	Mörl, Falk, Günther, Michael, Rockenfeller, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9289520/ https://www.ncbi.nlm.nih.gov/pubmed/35860726 http://dx.doi.org/10.3389/fmed.2022.879120

Ejemplares similares

Where Have the Dead Gone?
por: Günther, Michael, et al.
Publicado: (2022)

Corrigendum: Where have the dead gone?
por: Günther, Michael, et al.
Publicado: (2023)

Reports of deaths are an exaggeration: all-cause and NAA-test-conditional mortality in Germany during the SARS-CoV-2 era
por: Rockenfeller, R., et al.
Publicado: (2023)

Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment
por: Aschmann, Hélène E, et al.
Publicado: (2019)

Giraffes and hominins: reductionist model predictions of compressive loads at the spine base for erect exponents of the animal kingdom
por: Günther, Michael, et al.
Publicado: (2021)

Ketamine for the treatment of prehospital acute pain: a systematic review of benefit and harm
por: Sandberg, Mårten, et al.
Publicado: (2020)

Benefit‐to‐harm ratio of the Danish breast cancer screening programme
por: Beau, Anna‐Belle, et al.
Publicado: (2017)

Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency
por: Orellana García, Laura Patricia, et al.
Publicado: (2021)

Benefits and harms of mammography screening
por: Løberg, Magnus, et al.
Publicado: (2015)

Predicting Regulatory Product Approvals Using a Proposed Quantitative Version of FDA’s Benefit–Risk Framework to Calculate Net-Benefit Score and Benefit–Risk Ratio
por: Sun, Stephen, et al.
Publicado: (2020)

Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol
por: Li, Guowei, et al.
Publicado: (2015)

ACE/ACE2 Ratio: A Key Also in 2019 Coronavirus Disease (Covid-19)?
por: Pagliaro, Pasquale, et al.
Publicado: (2020)

The Approved Societies and Their Medical Referees
Publicado: (1913)

Preprints in Medicine: Useful or Harmful?
por: Bonnechère, Bruno
Publicado: (2020)

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs
por: Bloem, Lourens T., et al.
Publicado: (2022)

Combined Benefit of Prediction and Treatment: A Criterion for Evaluating Clinical Prediction Models
por: Billheimer, Dean, et al.
Publicado: (2014)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

TRIOLOGY ACS: No benefit/No harm
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2013)

Benefits and harms of lower blood pressure treatment targets: systematic review and meta-analysis of randomised placebo-controlled trials
por: Brunström, Mattias, et al.
Publicado: (2019)

Benefits and Harms of COVID-19 Vaccines in Cardiovascular Disease: A Comprehensive Review
por: Chen, Chung-Yen, et al.
Publicado: (2023)

Comparative Sensitivity Analysis of Muscle Activation Dynamics
por: Rockenfeller, Robert, et al.
Publicado: (2015)

Corrigendum to “Comparative Sensitivity Analysis of Muscle Activation Dynamics”
por: Rockenfeller, Robert, et al.
Publicado: (2017)

The Vaccination Papers Approved
por: Dillingham, Thomas M.
Publicado: (1898)

The comparative analysis of statistics, based on the likelihood ratio criterion, in the automated annotation problem
por: Leontovich, Andrey M, et al.
Publicado: (2008)

Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study
por: Qin, Shuxia, et al.
Publicado: (2022)

Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model
por: Pashayan, Nora, et al.
Publicado: (2018)

Critical Overview on the Benefits and Harms of Aspirin
por: Kwok, Chun Shing, et al.
Publicado: (2010)

Regulatory Approval With Real-World Data From Regulatory Science Perspective in Japan
por: Maeda, Hideki, et al.
Publicado: (2022)

Extending Age Ranges in Breast Cancer Screening in Four European Countries: Model Estimations of Harm-to-Benefit Ratios
por: Zielonke, Nadine, et al.
Publicado: (2021)

Protective or Harmful: The Dual Roles of Autophagy in Diabetic Retinopathy
por: Gong, Qiaoyun, et al.
Publicado: (2021)

International oncology drug approvals for multiregional or single-country clinical trials: A systematic review
por: Zhang, Min, et al.
Publicado: (2022)

Design and approval of the nutritional warnings’ policy in Peru: Milestones, key stakeholders, and policy drivers for its approval
por: Diez-Canseco, Francisco, et al.
Publicado: (2023)

Rapid elimination of cervical cancer while maintaining the harms and benefits ratio of cervical cancer screening: a modelling study
por: Jansen, Erik E. L., et al.
Publicado: (2022)

(13)C-NMR Chemical Shifts in 1,3-Benzazoles as a Tautomeric Ratio Criterion
por: García-Báez, Efrén V., et al.
Publicado: (2022)

Can Neutrophil-Lymphocyte Ratio Be a Useful Criterion for Neuroleptic Malignant Syndrome in the Absence of Leukocytosis?
por: Kalelioglu, Tevfik, et al.
Publicado: (2021)

Benefits and harms of high-dose haemodiafiltration versus high-flux haemodialysis: the comparison of high-dose haemodiafiltration with high-flux haemodialysis (CONVINCE) trial protocol
por: Blankestijn, Peter J, et al.
Publicado: (2020)

Clinical benefit of cancer drugs approved in Switzerland 2010–2019
por: Adam, Roman, et al.
Publicado: (2022)

The Potential Benefit of Expedited Development and Approval Programs in Precision Medicine
por: Kantor, Ariel, et al.
Publicado: (2021)

Oxidative Stress: Harms and Benefits for Human Health
por: Pizzino, Gabriele, et al.
Publicado: (2017)

Sun Exposure in Children: Balancing the Benefits and Harms
por: Jindal, Ankur K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qpsril5mp6b1hq4ggb40rpkm7s